Skip to main content

Market Overview

Why This Analyst Thinks Gilead's Technicals Are Setting Up For A Break

Share:

Anne-Marie Baiynd was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

With the news Friday that Gilead Sciences, Inc.'s (NASDAQ: GILD) drugs Sovaldi and Harvoni may cause heart trouble in patients also on amiodarone, analyst Ann-Marie Baiynd took a look at what the technicals might say. Baiynd said that Gilead is in a wedge formation, and expects that "something is going to break." Given a choice between the long and short sides, Baiynd expects the stock to move lower.

The stock has bounced off the pre-market lows, but Baiynd warned that the morning action was a "big red flashing sign." Whereas in the past, Baiynd always felt comfortable with buying the stock at $98 to $99, she urged caution on this go around.

Related Link: Gilead Shares Tumble On Drug Warning; Baird Says Buy

Baiynd expects the stock to fail at the $101 and $102 level, before moving lower to $95 and $96. If the stock moves below the $95.80 level, "it will really be the kicker."

Shares traded recently at $100.37, down 1.88 percent on the day.

Check out the full interview below:

 

Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Short Ideas Technicals Exclusives Movers Trading Ideas General

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com